Younger (<50 years old) or later stage (stages III and IV) patients were associated with higher risk of progression, although the effect of age was only marginally significant.
← all excerpts
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel.
1
—
—